secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0001404644-24-000029
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene Reports Positive Initial Safety Data from Phase 1/2 Gene Therapy Trial for Rett Syndrome
--------------------------------------------------------------------------------

- NGN-401 generally well-tolerated in three patients with multiple months of follow-up.
- No treatment-emergent or procedure-related serious adverse events or MeCP2 overexpression toxicity observed.
- Data presented at ASGCT Annual Meeting; includes one patient with mild variant predicted to retain residual MeCP2 function.
- Company expects interim efficacy readout in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000029/0001404644-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000029/ngne-20240422.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer